Extraintestinal manifestations of inflammatory bowel disease

Problems in General Surgery

Volumn 16, Issue 2, 1999, Pages 23-39

  Lichtenstein, David R ^a,b   Park, Peter D ^b   Lichtenstein, Gary R ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHROPATHY; CROHN DISEASE; ENTERITIS; EYE DISEASE; GALLSTONE; HUMAN; MALABSORPTION; MOUTH DISEASE; NEPHROLITHIASIS; OBSTRUCTIVE UROPATHY; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; ULCERATIVE COLITIS;

EID: 0032976395     PISSN: 07398328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. Monsen U, Sorstad J, Hellers G, et al. Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 1990;85:711-6.
2. Rankin GB, Watts HD, Melynk CS, Kelley ML. The National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979;77:914-20.
3. Greenstein AJ, Janowith HD, Sachar DB. The extraintestinal manifestations of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976; 55:401-12.
4. Farmer RG, Hawk WA, Turnball RB. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975;68:627-35.
5. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory disease. J Clin Gastroenterol 1996;23:29-34.
6. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol 1988;83:703-709.
7. Orchard TR, Wordsworth BP, Jewel DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998;42: 387-91.
8. Haslock I, Wright V. The musculo-skeletal complications of Crohn's disease. Medicine 1973;52:217-25.
9. Van den Broek MF, van de Putte LB, vanden Berg WB. Crohn's disease associated with arthritis: a possible role for cross-reactivity between gut bacteria and cartilage in the pathogenesis of arthritis. Arthritis Rheum 1988;31:1077-9.
10. Kaufmann HJ, Tqubin HL. Non-steroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513-6.
11. Davis P, Thompson A, Lentle B. Quantitative sacroiliac scintigraphy in patients with Crohn's disease. Arthritis Rheum 1978;21:234-7.
12. Weiner SR, Clare U, Taggart N.A. Rheumatic manifestations of inflammatory bowel disease. Semin Arthritis Rheum 1991;20:353-66.
13. Van den Linden S. Ankylosing spondylitis. In: Kelley WN, ed. Textbook of rheumatology. 5th ed. Philadelphia: Saunders, 1997:983-97.
14. Brewerton DA, James DCO. Histocompatibility antigen (HLA-27) and disease. Semin Arthritis Rheum 1975;4:191-203.
15. Mir-madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol 1985;80: 615-20.
16. McCallum DI, Kinmont PDC. Dermatological manifestations of Crohn's disease. Br J Dermatol 1968; 80:1-8.
17. White JW. Erythema nodosum. Dermatol Clin 1985; 3:119-27.
18. Schoetz DJ, Coller JA, Veidenheimer MC. Pyoderma gangrenosum and Crohn's disease: eight cases and Review of the literature. Dis Colon Rectum 1983;26: 155-8.
19. Finkel SI, Janowitz HD. Trauma and the pyoderma gangrenosum of inflammatory bowel disease. Gut 1981;22:410-2.
20. Gellert A, Green ES, Beck ER, et al. Erythema nodosum progressing to Pyoderma Gangrenosum as a Complication of Crohn's disease. Postgrad Med J 1983;59:791-3.
21. Johnson ML, Wilson HTH. Skin lesions in ulcerative colitis. Gut 1969;10:255-263.
22. Cook TJ, Lorincz AL. Pyoderma gangrenosum appearing ten years after colectomy and apparent cure of chronic ulcerative colitis. Arch Dermatol 1962;86: 105-6.
23. Van Hale HM, Rogers RS, Zone JJ, Greippo PR. Pyostomatitis vegetans: a reactive mucosal marker in inflammatory disease of gut. Arch Dermatol 1985;121: 94-8.
24. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis and Crohn's disease and ulcerative colitis. Br J Dermatol 1982;106: 302-30.
25. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990;85:962-3.
26. Brenner SM, Delany HM. Erythema multiforme and Crohn's disease of the large intestine. Gastroenterology 1972;62:479-82.
27. Cheesbrough MJ, Kinmont PDC. Epidermolysis bullosa acquisita and Crohn's disease. Br J Dermatol 1978;99(suppl 16):66-7.
28. Hopkins DJ, Horan E, Burton IL, et al. Ocular disorders in a series of 332 patients with Crohn's disease. Br J Opthalmol 1974;58:732-7.
29. Knox DL, Schachat AP, Mustonen E. Primary, secondary and coincidental ocular complications of Crohn's disease. Ophthalmology 1984;91:163-73.
30. Salmon JF, Wright JP, Murray AD. Ocular inflammation in Crohn's disease. Ophthalmology 1991;98: 480-4.
31. Petrelli EA, McKinley M, Troncale FJ: Ocular manifestations of inflammatory bowel disease. Ann Ophthalmol 1982;14:356-60.
32. Levine JB: Arthropathies and ocular complications of inflammatory bowel disease. In: Targan S, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore, MD: Williams & Wilkins, 1994: 450-60.
33. Johnston CC, Slemenda CW, Melton LH. Clinical use of bone densitometry. N Eng J Med 1991;324:1105-9.
34. Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997;32:1247-55.
35. Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992;37:1396-404.
36. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410-5.
37. Hessov I, Mosekilde L, Melsen F, Fasth S, Hulten L, Lund B, Sorensen OH. Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. Scan J Gastroenterol 1984;19:691-6.
38. Motley RJ, Clements D, Evans WD, Crawley EO, Evans C, Rhodes J, Compston JE. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993;23:95-104.
39. Abitol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995;108:417-22.
40. Driscoll RH, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with crohn's disease. Gastroenterology 1982;83:1252-8.
41. Vogelsang H, Ferenci P, Woloszeznk W, et al. Bone disease in vitamin D deficient patients with Crohn's disease. Dig Dis Sci 1989;34:1094-9.
42. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993;34: 1543-6.
43. Vogelsang H. Prevention of bone mineral loss in patients with Crohn's disease by long term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7:609-14.
44. Dyer NH, Child JA, Mollin DL, et al. Anemia in Crohn's disease. Q J Med 1972;41:419-36.
45. Elsborg L, Larsen L. Folate deficiency in chronic inflammatory bowel disease. Scand J Gastroenterol 1979;14:1019-24.
46. Gumaste V, Greenstein AJ, Meyers R, et al. Coombspositive autoimmune hemolytic anemia in ulcerative colitis. Dig Dis Sci 1989;34:1457-61.
47. Altman AR, Maltz CR, Janowitz HD. Autoimmune hemolytic anemia in ulcerative colitis. Dig Dis Sci 1979; 24:282-5.
48. Talstad I, Rootwelt K, Gjone E. Thrombocytosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1973;8:135-8.
49. Pena JM, Gonzales-Garcia JJ, Garcia-Alegria J, et al. Thrombocytopenia and sulfasalazine. Ann Intern Med 1985;102:277-8.
50. Das KM, Eastwood MA, McManus JPA, et al. Adverse reactions during salicyazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491-5.
51. Colona T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine induced remission of refractory Crohn's disease. Am J Gastroenterol 1994;89:362-6.
52. Talbot RW, Heppell J, Dozois RR, Beart RW. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986;61:140-5.
53. Dennis C, Karlson KE. Surgical Measures as supplements to the management of idiopathic ulcerative colitis: cancer, cirrhosis, and arthritis as frequent complications. Surgery 1952;32:892-912.
54. Groef V, Boggenstosis AH, Sauer WG, Spittel JA. Venous thrombosis occurring in non-specific ulcerative colitis. Arch Intern Med 1966;117:377-82.
55. Lake AM, Stautter JQ, Stuart MJ. Hemostatic alterations in inflammatory bowel disease: response to therapy. Am J Dig Dis 1978;23:897-902.
56. Lam A, Borda IT, Inwood MJ, Thomson S. Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology 1975;68:245-51.
57. Liebman HA, Kashani N, Sutherland D, McGehee W, Kam L. The factor V leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterology 1998;115:830-4.
58. Gaffney PR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995; 90:220-3.
59. Banner MP. Genitourinary complications of inflammatory bowel disease. Radiol Clin North Am 1987;25: 199-209.
60. Gelzayd EA, Breuer RI, Kirsner JB. Nephrolithiasis in inflammatory bowel disease. Am J Dig Dis 1968; 13:1027-34.
61. Deren JJ, Porush JG, Levitt MF, et al. Nephrolithiasis as a complication of ulcerative colitis and regional enteritis. Ann Intern Med 1962;56:843-53.
62. Smith LH, Fromm H, Hofmann AF: Acquired hyperoxaluria, nephrolithiasis, and intestinal disease: description of a syndrome. N Engl J Med 1972;286:1371-5.
63. Hofmann AF, Thomas PJ, Smith LH, et al. Pathogenesis of secondary hyperoxaluria in patients with ileal resection and diarrhea [abstract]. Gastroenterology 1970;58:960A.
64. Present D, Rabinowitz J, Banks P, Janowitz H. Obstructive hydronephrosis: a frequent but seldom recognized complication of granulomatous disease of the bowel. N Engl J Med 1969;280:523-8.
65. Gitkind MJ, Wright SC. Amyloidosis complicating inflammatory bowel disease. Dig Dis Sci 1990;35:906-8.
66. Greenstein AJ, Sachar DB, Panday et al. Amyloidosis and inflammatory bowel disease: a 50 year experience with 25 patients. Medicine 1992;71:261-70.
67. Becker SA, Bass D, Nissim F. Crohn's ileitis complicated by amyloidosis: observations and therapeutic considerations. J Clin Gastroenterol 1985;7:296-300.
68. Meyers S, Janowitz HD, Gumaste V, et al. Colchicine therapy of the renal amyloidosis of ulcerative colitis. Gastroenterology 1988;94:1503-7.
69. Lovat LB, Madhoo S, Pepys MB, et al. Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology 1997;112:1362-5.
70. Mandelstam P, Simmons DE, Mitchell B. Regression of amyloid in Crohn's disease after bowel resection. J Clin Gastroenterol 1989;11:324-6.
71. Fitchen JH. Amyloidosis and granulomatous ileocolitis: Regression after removal of the involved bowel. N Engl J Med 1975;292:352-3.
72. Patwardhan RV, Heilpern J, Brewster AC, et al: Pleuropericarditis: an extraintestinal complication of inflammatory bowel disease. Arch Intern Med 1983;143: 94-96
73. Rheingold OJ. Inflammatory bowel disease and pericarditis. Am Intern Med 1975;82:592.
74. Gujral J, Friedenberg F, Friedenberg J, Gabriel G, Kotler M, Levine G. Pleuropericarditis related to the use of mesalamine. Dig Dis Sci 1996;41:624-6
75. Agnholt J, Soerensen HT, Rasmussen SN, et al. Cardiac hypersensitivity to 5-aminosalicylic acid. Lancet 1989;2:1135.
76. Eade OE, Smith CL, Alexander JR, Whorwell PJ. Pulmonary function tests in patients with inflammatory bowel disease. Am J Gastroenterol 1980;73:154-6.
77. Forrest JA, Shearman DJ. Pulmonary vasculitis and ulcerative colitis. Am J Dig Dis 1975;20:482-6.
78. McKee AL, Rajepaksar A, Kalish PE, Pitchumoni CS. Severe interstitial pulmonary fibrosis in a patient with chronic ulcerative colitis. Am J Gastroenterol 1983;78: 86-9.
79. Gendelman S, Present D, Janowitz HD. Neurological complications of inflammatory bowel disease [abstract]. Gastroenterology 1982;82:1065A.
80. Dejaco C, Fertl E, Prayer D, Oberhuber G, Wyatt J, Gasche C, Gangl A. Symptomatic cerebral microangiopathy preceding initial manifestation of ulcerative colitis. Dig Dis Science 1996;41:1807-10.
81. Johns D. Cerebrovascular Complications of inflammatory bowel disease. Am J Gastroenterol 1991;86: 367-70.
82. Shum DT, Guenther L. Metastatic Crohn's disease: a case report and review of the literature. Arch Dermatol 1990;126:645-8.
83. Tweedie JH, McCannon BG. Metastatic Crohn's disease of the thigh and forearm. Gut 1984;25:213-4.
84. Kafity AA, Pelligrini AE, Fromkes JJ. Metastatic Crohn's disease: a rare cutaneous manifestation. J Clin Gastroenterol 1993;17:300-3.
85. McCallum DI, Gray WM. Metastatic Crohn's disease. Br J Dermatol 1976;95:551-4.
86. Phillips RKS, Glazer G. Metastatic Crohn's disease of the umbilicus. Br Med J 1981;283:887.
87. Slaney G, Muller S, Clay J, Sumathipala AHT, Hillenbrand P, Thompson H. Crohn's disease involving the penis. Gut 1986;27:329-33.
88. Lebwohl M, Fleischmajer R, Janowitz H, et al. Metastatic Crohn's disease. J Am Acad Dermatol 1984;10:33-8.
89. Lavery HA, Pinkerton JHM, Sloan J. Crohn's disease of the vulva: two further cases. Br J Dermatol 1985; 113:359-63.
90. Slater DN, Waller PC, Reilly G. Cutaneous granulomatous vasculitis: presenting feature of Crohn's disease. J R Soc Med 1985;78:589-90.
91. Perret CM, Bahmer FA. Extensive necrobiosis in metastatic Crohn's disease. Dermatologica 1987;175: 208-12.
92. Van Dullmen HM, de Jong E, Slors F, Tytgat GN, van Deventer SJ. Treatment of therapy-resistant perineal metastatic Crohn's disease after proctectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2: report of two cases. Dis Colon Rectum 1998;41:98-102.
93. Helzberg JH, Peterson JM, Boyer JL. Improved survival with primary sclerosing cholangitis: a review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology 1987;92:1869-75.
94. Wiesner RH, La Russo NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980;79:200-6.
95. Young-Mee L, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995;332:924-33.
96. Cangemi JR, Wiesner RH, Beaver SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 1989;96:790-4.
97. LaRusso NF, Weisner RH, Ludwig J, et al. Primary sclerosing cholangitis. N Engl J Med 1984;310:899-903.
98. Stockbrugger RW, Olsson R, Jaup B, et al. Forty six patients with primary sclerosing cholangitis: radiological bile duct changes in relationship to clinical course and concomitant inflammatory bowel disease. Hepatogastroenterology 1988;35:289-94.
99. Palmer KR, Duerden BI, Holdsworth CD. Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. Gut 1980;21:851-4.
100. Siegel JH, Barnes S, Morris JS. Bile acids in liver disease associated with inflammatory bowel disease. Digestion 1977;15:469-81.
101. Gross JR, Ludwig J, Weisner RH, et al. Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology 1985;89:272-8.
102. LaRusso NF, Weisner RH, Ludwig J, et al. Prospective trial of Penicillamine in primary sclerosing cholangitis. Gastroenterology 1988;95:1036-42.
103. Wiesner RH. Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 1994;69:969-82.
104. Crippin JS, Lindor KD. Primary sclerosing cholangitis: etiology and immunology. Eur J Gastroenterol Hepatol 1992;4:261-5.
105. Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on humal colon, skin and biliary epithelium detectedby a monoclonal antibody. Gastroenterology 1980;98:464-9.
106. Duerr RH, Targan SR, Landers CJ, et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991;100:1385-91.
107. Klein R, Eisenburg J, Weber P, et al. Significance and specificity of antibodies to neutrophils detected by Western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatology 1991;14: 1147-52.
108. Seibold F, Weber P, Klein R, et al. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 1992;33:657-62.
109. Bodenheimer HC, Jr, LaRusso NF, Thayer WR, et al. Eleveted circulating immune complexes in primary sclerosing cholangitis. Hepatology 1983;3:150-4.
110. Alberti-Florr JJ, De Medina M, Jeffers L, et al. Elevated immunoglobulins and immune complexes in the bile of patients with primary sclerosing cholangitis. Am J Gastroenterol 1986;81:325-8.
111. Senaldi G, Donaldson PT, Margin S, et al. Activation of the complement system in primary sclerosing cholangitis. Gastroenterology 1989;97:1430-4.
112. Snook JA, Chapman RW, Sachdev GK, et al. Peripheral blood and portal tract lymphocyte populations in primary sclerosing cholangitis. J Hepatol 1989;9:36-41.
113. Whiteside TL, Lasky S, Si L, et al. Immunological analysis of monopnuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. Hepatology 1985;5:468-74.
114. Lindor KD, Wiesner RH, LaRusso NF, et al. Enhanced autoreactivity of T-lymphocytes in primary sclerosing cholangitis. Hepatology 1987;7:884-8.
115. Balan V, LaRusso NF. Hepatobiliary disease in inflammatory bowel disease. Gastroenterol Clin N Am 1995;24:647-69.
116. Fausa O, Schrumpf E, Elgio K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991;11:31-9.
117. Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610-5.
118. Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100:1710-17.
119. Dickson ER, Murtagh PA, Wiesner RH, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992;103:1893-1901.
120. Abu-Elmgad KM, Malinchoc M, Dickson ER, et al. Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg Gyn Obstet 1993; 177:335-44.
121. Fleming KA. The hepatobiliary pathology of primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 1992;4:266-71.
122. Olsson R, Hagerstand I, Broome U, et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol 1995;48:933-5.
123. Myers RN, Cooper TH, Padis N. Primary Sclerosing Cholangitis. Complete gross and histological reversal after long term steroid therapy. Am J Gastroenterol 1970;53:527-38.
124. Knox TA, Kaplan MM. Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 1991;86:546-52.
125. Knox TA, Kaplan MM. A double blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994;106:494-9.
126. Lindor KD, Jorgensen RA, Anderson ML, et al. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 1996;91:511-5.
127. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455-9.
128. Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial. Hepatology 1992;16:707-14.
129. Stiehl A, Walker S, Stiehl L, et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis: a 3 year pilot study with a placebo controlled study period. J Hepatol 1994;20:57-64.
130. Lindor KD. The Mayo PSC/UDCA study group. Ursodiol for primary sclerosing cholangitis. N Eng J Med 1997;336:691-5.
131. Bergasa NV, Jones EA. The pruritis of cholestasis. Semin Liver Dis 1993;13:319-27.
132. Bergasa NV, Talbot TL, Alling DW, et al. A controlled trial of naloxone infusions forthe pruritis of chronic cholestasis. Gastroenterology 1992;102:544-9.
133. Hay JE, Lindor KD, Wiesner RH, et al. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991;14:257-61.
134. Pokorny CS, McCaughan GW, Gallagher ND, et al. Sclerosing cholangitis and biliary tract calculi: primary or secondary? Gut 1992;33:1376-80.
135. Ponsioen CIJ, Tytgat GNJ. Primary sclerosing cholangitis: a clinical review. Am J Gastroenterol 1998;93: 515-23.
136. Gaing AA, Geders JM, Siegel JH, et al. Endoscopic management of primary sclerosing cholangitis: review and report of an open series. Am J Gastroenterol 1993;88:2000-8.
137. Johnson GK, Geenen JE, Venu RP, et al. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc 1991;37:38-43.
138. Lee JG, Schutz SM, England RE, Leung JW, Cotton PB. Endoscopic therapy of sclerosing cholangitis. Hepatology 1995;21:661-7.
139. Van Milligen de Wit AWM, Van Bracht J, Rauws EAJ, et al: Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1996;44:293-9.
140. Van Milligen de Wit AWM, Rauws EAJ, Bracht J, et al. Lack of complications following short term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 1997; 46:344-7.
141. Rosen CB, Nagorney DM, Wiesner RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991;213:21-5.
142. Marsh JW, Iwatsuki S, Makowka L, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg 1988;207:21-5.
143. Ferrari AP, Lichtenstein DR, Slivka A, et al. Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. Gastrointest Endosc 1994; 40:140-5.
144. Rogers SA, Poldolsky DK. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis: an analysis of serological marker CA 19-9. Hepatology 1994;19: 543-5.
145. Ismail T, Angrisani I, Powell JE, et al. Primary sclerosing cholangitis: surgical options, prognostic variables and outcome. Br J Surg 1991;78:564-7.
146. Harrison RF, Davies MH, Neuberger JM, et al. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis? Hepatology 1994;20:356-61.
147. Sheng R, Zajko AB, Campbell WL, et al. Biliary strictures in hepatic transplants: prevalence and types in patients with primary sclerosing cholangitis vs those with other liver diseases. Am J Roentgenol 1993;161: 297-300.
148. Schrumph E, Fausa O, Elgjo K, et al. Hepatobiliary complications of Inflammatory Bowel Disease. Semin Liver Dis 1988;8:201-9.
149. Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? A study of 107 patients with chronic ulcerative colitis and hepatobiliary disease. Ann Intern Med 1985; 102:581-7.
150. Greenstein AJ, Janowitz HD, Sachar DB. The extraintestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976; 55:401-12.